**Core Concept**
Tardive dyskinesia is a side effect of long-term antipsychotic medication use, characterized by involuntary, repetitive body movements. The pathophysiology involves dopamine receptor blockade, particularly D2 receptors in the basal ganglia, leading to an imbalance in the dopaminergic system.

**Why the Correct Answer is Right**
Deutetrabenazine (Valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which depletes dopamine and serotonin from the synaptic cleft, thereby reducing the abnormal movements associated with tardive dyskinesia. This mechanism is distinct from the traditional dopamine receptor antagonists used in antipsychotic medications. By reducing the amount of dopamine available, deutetrabenazine helps to alleviate the symptoms of tardive dyskinesia.

**Why Each Wrong Option is Incorrect**
* **Option A:** Incorrect because it does not specifically target the underlying pathophysiology of tardive dyskinesia.
* **Option B:** Incorrect because it is not a known treatment for tardive dyskinesia.
* **Option C:** Incorrect because it is actually a type of medication that can contribute to the development of tardive dyskinesia, rather than treating it.

**Clinical Pearl / High-Yield Fact**
Deutetrabenazine is a relatively new addition to the treatment armamentarium for tardive dyskinesia, and its unique mechanism of action sets it apart from traditional antipsychotics. It is essential to recognize the potential for tardive dyskinesia as a side effect of long-term antipsychotic use and to consider deutetrabenazine as a treatment option in these cases.

**Correct Answer: D. Deutetrabenazine (Valbenazine)**